Sutro Biopharma Inc (NASDAQ:STRO) has prioritized three wholly owned pre-clinical programs in its next-generation ADC pipeline, indicating a focused strategic direction. The company's cash runway ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback